FDA Details National Vaccine Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Details National Vaccine Plan


Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014. Midthun points out how crucial vaccines are in protecting public health and discusses FDA’s role in ensuring a stable supply of safe vaccines.

According to Midthun, the National Vaccine Plan plans on developing new vaccines, enhancing the vaccine safety system, supporting enhanced communication regarding vaccine decision-making, ensuring a stable supply of vaccines, and increasing global prevention of disease through vaccination. The National Vaccine Program Office recently issued the State of the National Vaccine Plan, which details the government’s progress regarding the vaccine plan. Some of the accomplishments listed in the report include the establishment of a new generation of influenza vaccines, new production techniques, and advances in electronic health data. Other accomplishments include the establishment of Vaccines.gov and vaccine promotional materials.

The report states that the National Vaccine Plan will continue in the coming years with more research into new vaccines, extension of monitoring systems, and continued development of communication paths. The report can be found on the HHS website.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here